Fig. 1: CD51 is associated with the poor outcome of PCa patients.
From: p53-dependent CD51 expression contributes to characteristics of cancer stem cells in prostate cancer
a Immunohistochemistry (IHC) analyses showed that CD51 expression level was gradually increased with the Gleason score. Scale bar: 100 μm. b Dot plot image showing the positive association of CD51 expression with the Gleason score in PCa, as determined by Spearman correlation. c The Cancer Genome Atlas (TCGA) PCa gene expression data set was sorted by CD51 expression and presented in the dot plot image. The top and bottom quartiles (CD51 low and high, respectively) were selected. Positive and negative lymph node metastasis groups were found to have significantly different CD51 expression (p < 0.001, t-test, two tailed). d Kaplan–Meier survival analysis of PFS between the CD51+ (n = 112) and CD51− (n = 54) groups. Median PFS of 20 (CD51+) vs. 24 (CD51−) months for PCa patients (hazard ratio (HR), 0.379; 95% CI, 0.1592–0.9036; p = 0.028)
